drugset / Trial / NCT06378957

Behavioral Pharmacology of Orally Administered THC and D-limonene

NCT06378957

Phase 1 Recruiting 65 enrolled Johns Hopkins University
RandomizedCrossoverDouble-blindBasic science

Summary

The current clinical trial will investigate the effects of orally administered d-limonene (limonene), delta-9-tetrahydrocannabinol (THC) and the combination in healthy adult volunteers.

Timeline

Start
2025-02-14
Primary completion
2027-07-01
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Dronabinol Other / unclassified 30 mg Oral
Subject d-limonene Small molecule 25 mg Oral
Subject d-limonene Small molecule 50 mg Oral
Subject d-limonene Small molecule 100 mg Oral
Subject d-limonene Small molecule 200 mg Oral

Indications

No indication recorded.